Morgan Stanley Vallon Pharmaceuticals, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.22 - $0.52 $19 - $46	90 New	90 $0
Q2 2022 Oct 27, 2022	SELL	$0.42 - $2.27 $819 - $4,431	-1,952 Reduced 97.5%	50 $0
Q2 2022 Aug 15, 2022	SELL	$0.42 - $2.27 $819 - $4,431	-1,952 Reduced 97.5%	50 $0
Q1 2022 Oct 27, 2022	BUY	$1.79 - $8.0 $3,494 - $15,616	1,952 Added 3904.0%	2,002 $4,000
Q1 2022 May 13, 2022	SELL	$1.79 - $8.0 $1,120 - $5,008	-626 Reduced 23.82%	2,002 $4,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $9.68 $10,117 - $25,439	2,628 New	2,628 $19,000

Ticker VLON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,512,800
Description
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.